| Field | Specification |
|---|---|
| Alternative names | CAD-1883 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C18H24F2N6O |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Rimtuzalcap, also known as CAD-1883, is a first-in-class, selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). It can be used to research movement disorders, including essential tremor (ET) and spinocerebellar ataxia (SCA)[1]. It is supplied as a white to off-white solid (C18H24F2N6O, MW 378.42) at 99.27% purity.
Physical & Chemical Properties
| CAS Number | 2167246-24-2 |
|---|---|
| Molecular Formula | C18H24F2N6O |
| Molecular Weight | 378.42 g/mol |
| Purity | 99.27% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | CC1=NN(C2=NC(N3CCOCC3)=CC(NC4CCC(F)(F)CC4)=N2)C=C1 |
| Signaling Pathway | Membrane Transporter/Ion Channel |
| Solubility | In Vitro: DMSO: 250 mg/mL (660.64 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, protect from light. In solvent: -80°C, 6 months; -20°C, 1 month (protect from light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Crystalline forms of potassium channel modulators. WO2020086456A1.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 250 mg/mL (660.64 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); protect from light; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.50 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (5.50 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.08 mg/mL (5.50 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Rimtuzalcap acts as a small molecule modulator of potassium ion channels with great therapeutic potential for treating various diseases characterized by potassium ion channel dysfunction, as well as dysfunction from other causes that influence these channels[1].
In Vivo
Rimtuzalcap (CAD-1883) lowers the firing rate of Purkinje cells by approximately 40%, matching the expected therapeutic mechanism, positive allosteric modulation of SK channels. In cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice, sequential bath application of 1 or 3 μM CAD-1883 partially reverses the increased coefficient of variation of the interspike interval seen in those slices[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Nat Commun. 2026 Jan 8;17(1):531.
Structural basis for the subtype-selectivity of KCa2.2 channel activators. Res Sq 2025 May 16:rs.3.rs-6568445. PMID: 40470184
